Clinical-stage Opportunity Auron Therapeutics is a clinical-stage biotechnology company actively advancing lead asset AUTX-703 for blood cancers, supported by recent Series B funding and leadership hires. This presents a near-term opportunity to engage on translational and early clinical collaboration, companion diagnostics, and potential CRO/CMC support as they enter development milestones.

Funding Momentum With a combined Series B funding of over 40 million ($13.4M in 2024 and $27M in 2025) and a presence at industry events, Auron is investing in clinical development and data generation. This suggests a window for CAPEX-light partnerships, research alliances, and potential commercial collaboration discussions aligned with their clinical timelines.

Disease Focus Auron targets cell-state plasticity to treat solid tumors and hematologic malignancies, including presentations at small cell lung cancer meetings. This indicates potential fit for diagnostic assays, biomarker development, and targeted screening programs that align with their precision oncology platform.

Strategic Partnerships Recent executive hires and expansion into leadership roles (CFO appointment in 2025, Chief Scientific/Data/People Officers previously) signal a readiness for broader strategic collaborations, licensing opportunities, and joint ventures to scale from discovery to clinical testing and regulatory submission.

Engagement avenues Active participation in targeted protein degradation and induced proximity summits, plus public disclosures of posters and data, open channels for academic and contract research partnerships, access to their AURIGIN platform, and opportunities to co-develop or validate biomarkers and novel small molecules.